Expression of HER2-neu, SKP2 and HIF-1 and their role in predicting the response of muscle invasive urothelial carcinoma to bladder- preservation chemotherapy

Abstract

response to therapy. This study aimed to assess Top II, KI67 and P53 expression on clinical outcome and response to therapy of non-muscle invasive urothelial carcinoma. Methods: Fifty cases of non-muscle invasive urothelial carcinoma were collected; Top II, KI67, and P53 expression were evaluated. Patients received treatment then recurrence was correlated with the expression of previous markers. Results: There was a significant association between high Top II score, P53 and Ki67 and high grade (P ¼ 0.0001, 0.001, 0.0001), submucosal infiltration (P ¼ 0.0001, 0.01) and recurrence (P ¼ 0.01, 0.001, 0.001). Conclusions: Top II, P53, and Ki-67 may predict response to therapy and the clinical outcome in non-muscle invasive urothelial carcinoma.Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.13P Expression of HER2-neu, SKP2 and HIF-1 and their role in predicting the response of muscle invasive urothelial carcinoma to bladderpreservation chemotherapy